Bacteremia - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Bacteremia – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bacteremia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Bacteremia: Overview
Bacteremia refers to the presence of live bacteria in the blood. Bacteremia may result from ordinary activities (such as vigorous toothbrushing), dental or medical procedures, or from infections (such as pneumonia or a urinary tract infection). Usually, bacteremia that results from ordinary events, such as dental procedures, is temporary and causes no symptoms. Bacteremia that results from other conditions may cause fever. Bacteremia may occur during: Certain ordinary activities, Dental or medical procedures, certain bacterial infections, and Injection of recreational drugs. Identifying or presuming the source of infection will dictate the diagnostic measures taken. People who are at high risk of complications due to bacteremia (such as those who have an artificial heart valve or joint or certain heart valve abnormalities) are often given antibiotics. Bacteremia requires urgent and appropriate antibiotics. Delay in the administration of appropriate antibiotics is associated with increased morbidity and mortality.
'Bacteremia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bacteremia pipeline landscape is provided which includes the disease overview and Bacteremia treatment guidelines. The assessment part of the report embraces, in depth Bacteremia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bacteremia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Bacteremia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Bacteremia Emerging Drugs
Further product details are provided in the report
Bacteremia: Therapeutic Assessment
This segment of the report provides insights about the different Bacteremia drugs segregated based on following parameters that define the scope of the report, such as:
Bacteremia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bacteremia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bacteremia drugs.
Bacteremia Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Bacteremia – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bacteremia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Bacteremia: Overview
Bacteremia refers to the presence of live bacteria in the blood. Bacteremia may result from ordinary activities (such as vigorous toothbrushing), dental or medical procedures, or from infections (such as pneumonia or a urinary tract infection). Usually, bacteremia that results from ordinary events, such as dental procedures, is temporary and causes no symptoms. Bacteremia that results from other conditions may cause fever. Bacteremia may occur during: Certain ordinary activities, Dental or medical procedures, certain bacterial infections, and Injection of recreational drugs. Identifying or presuming the source of infection will dictate the diagnostic measures taken. People who are at high risk of complications due to bacteremia (such as those who have an artificial heart valve or joint or certain heart valve abnormalities) are often given antibiotics. Bacteremia requires urgent and appropriate antibiotics. Delay in the administration of appropriate antibiotics is associated with increased morbidity and mortality.
'Bacteremia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bacteremia pipeline landscape is provided which includes the disease overview and Bacteremia treatment guidelines. The assessment part of the report embraces, in depth Bacteremia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bacteremia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Bacteremia R&D. The therapies under development are focused on novel approaches to treat/improve Bacteremia.
This segment of the Bacteremia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Bacteremia Emerging Drugs
- Exebacase: ContraFect
- N-Rephasin SAL200:Intron Biotechnology
Further product details are provided in the report
Bacteremia: Therapeutic Assessment
This segment of the report provides insights about the different Bacteremia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Bacteremia
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Bacteremia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Bacteremia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Bacteremia drugs.
Bacteremia Report Insights
- Bacteremia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Bacteremia drugs?
- How many Bacteremia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Bacteremia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Bacteremia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Bacteremia and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Bacteremia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Bacteremia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Bacteremia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Bacteremia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Exebacase: ContraFect
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
N-Rephasin SAL200: Intron Biotechnology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
ETX2514: Entasis Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical stage products
Comparative Analysis
P 128 - GangaGen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Bacteremia Key Companies
Bacteremia Key Products
Bacteremia- Unmet Needs
Bacteremia- Market Drivers and Barriers
Bacteremia- Future Perspectives and Conclusion
Bacteremia Analyst Views
Bacteremia Key Companies
Appendix
Executive Summary
Bacteremia: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Bacteremia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Bacteremia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Bacteremia Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Exebacase: ContraFect
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
N-Rephasin SAL200: Intron Biotechnology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early Stage Products (Phase I)
Comparative Analysis
ETX2514: Entasis Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Preclinical stage products
Comparative Analysis
P 128 - GangaGen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Bacteremia Key Companies
Bacteremia Key Products
Bacteremia- Unmet Needs
Bacteremia- Market Drivers and Barriers
Bacteremia- Future Perspectives and Conclusion
Bacteremia Analyst Views
Bacteremia Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Bacteremia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Bacteremia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Bacteremia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Bacteremia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
